Top Strong Buy Stocks for November 13: PODD, PRAA, and Others
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 13 2025
0mins
Source: NASDAQ.COM
Zacks Rank #1 Stocks: Five stocks have been added to the Zacks Rank #1 (Strong Buy) List, including Preferred Bank, Weatherford International, Insulet Corporation, PRA Group, and Alexander's, all of which have seen significant increases in their earnings estimates over the past 60 days.
Market Growth in Data Centers: The demand for data is driving a new digital gold rush, with companies providing hardware for data centers expected to thrive, similar to how NVIDIA has succeeded in the semiconductor market.
Emerging Chipmaker: An under-the-radar chipmaker is positioned to benefit from the growth in the semiconductor market, focusing on products that larger companies like NVIDIA do not manufacture.
Investment Recommendations: Zacks Investment Research offers a free report on the "7 Best Stocks for the Next 30 Days," highlighting potential investment opportunities in the current market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PODD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PODD
Wall Street analysts forecast PODD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PODD is 375.83 USD with a low forecast of 316.00 USD and a high forecast of 450.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
19 Analyst Rating
18 Buy
1 Hold
0 Sell
Strong Buy
Current: 255.100
Low
316.00
Averages
375.83
High
450.00
Current: 255.100
Low
316.00
Averages
375.83
High
450.00
About PODD
Insulet Corporation is a medical device company. It is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, and the Omnipod Insulin Management System. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. It also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Healthcare Sector Declines 1.2%, Moderna Falls 7.2% Amidst Market Weakness
- Healthcare Sector Decline: As of midday Friday, the healthcare sector is down 1.2%, with Moderna Inc (MRNA) and Insulet Corp (PODD) showing losses of 7.2% and 4.5%, respectively, indicating overall sector weakness that may impact investor confidence.
- ETF Performance Analysis: The Health Care Select Sector SPDR ETF (XLV), which tracks the healthcare sector, is down 0.8% on the day but up 1.48% year-to-date, suggesting that despite short-term volatility, the long-term trend remains positive, potentially attracting investor interest.
- Moderna Year-to-Date Performance: Moderna Inc has risen 63.22% year-to-date, and despite the recent pullback, its strong annual performance may attract long-term investors, especially in the context of ongoing vaccine demand.
- Utilities Sector Performance: The utilities sector is also underperforming, down 1.0%, with AES Corp (AES) and Exelon Corp (EXC) showing declines of 2.7% and 2.0%, respectively, reflecting a weakening demand for defensive stocks in the current market environment.
Continue Reading
Insulet (PODD) Analysis: Market Trends and Investment Opportunities
- Market Trend Insights: In the latest Motley Fool Scoreboard episode, analysts delve into Insulet's market dynamics, offering unique insights into future investment opportunities that can help investors capitalize on potential gains.
- Investment Opportunity Assessment: The episode highlights Insulet's innovative products in diabetes management, which are expected to drive future growth, particularly against the backdrop of increasing global demand for diabetes treatments.
- Stock Price Reference: As of December 3, 2025, Insulet's stock price stood at 1.23%, reflecting a cautiously optimistic market outlook on its future performance, prompting investors to monitor its long-term growth potential.
- Video Content Sharing: The video, published on January 20, 2026, aims to provide viewers with the latest market analysis and investment advice, fostering a deeper understanding and interest in Insulet.
Continue Reading